Characteristics | n (%) | DL1 | DL2* | DL3 |
---|---|---|---|---|
n | n | n | ||
Total patient number | 20 (100) | 7 | 7 | 6 |
Gender | ||||
Male | 15 (75) | 4 | 6 | 5 |
Female | 5 (25) | 3 | 1 | 1 |
Age | ||||
Median Age – years (range) | 59 (34–72 ) | 57 (34–72) | 64 (43–67) | 57 (44–69) |
ECOG PS | ||||
ECOG PS 0 | 15 (75) | 5 | 7 | 3 |
Primary tumor site | ||||
Colon | 10 (50) | 4 | 5 | 1 |
Rectum | 10 (50) | 3 | 2 | 5 |
Previous adjuvant therapy | ||||
None | 17 (85) | 4 | 7 | 6 |
5-FU (infusional) | 3 (15) | 3 | 0 | 0 |
5-FU (bolus) | 1 (5) | 1 | 0 | 0 |
Oxaliplatin | 2 (10) | 2 | 0 | 0 |
Number of metastatic sites | ||||
Median number (range) | 1.75 (1–3) | 2.1 (1–3) | 1.7 (1–3) | 1.3 (1–2) |
KRAS status (retrospective) | ||||
Wild type | 14 (70) | 6 | 3 | 5 |
Mutant | 6 (30) | 1 | 4 | 1 |